{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:09:31Z","timestamp":1772118571576,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with\n                    <jats:sup>90<\/jats:sup>\n                    Yttrium\u2010ibritumomab tiuxetan (\n                    <jats:sup>90<\/jats:sup>\n                    Y\u2010IT) after re\u2010induction therapy with BR in patients with previously treated FL. This study included adult patients with relapsed FL who had undergone one or two prior therapies. Re\u2010induction therapy with BR was administered every 4 weeks up to 4\u20136 cycles. If patients achieved at least partial response,\n                    <jats:sup>90<\/jats:sup>\n                    Y\u2010IT was administered as consolidation therapy. The primary endpoint was 2\u2010year progression\u2010free survival (PFS) after consolidation. A total of 24 FL patients (median age 60 years) who had undergone one (\n                    <jats:italic>n<\/jats:italic>\n                    = 17) or two (\n                    <jats:italic>n<\/jats:italic>\n                    = 7) prior treatments received BR. After BR therapy, 22 patients proceeded to consolidation with\n                    <jats:sup>90<\/jats:sup>\n                    Y\u2010IT, resulting in an overall 88% response rate to the protocol treatment. Within a median observation period of 46.8 months, the estimated 2\u2010year PFS rate after the consolidation among the 22 patients receiving\n                    <jats:sup>90<\/jats:sup>\n                    Y\u2010IT was 59% (95% confidence interval [CI], 38%\u201377%). Patients whose remission after previous treatment had lasted \u22652 years had a significantly higher 2\u2010year PFS rate than patients whose remission after previous treatment had been &lt;2 years (68% vs. 33%, Wilcoxon\n                    <jats:italic>p<\/jats:italic>\n                    = 0.0211). Major adverse events during the protocol treatment and within 2 years after the consolidation were hematological toxicities, but they were generally acceptable. Consequently, the estimated 2\u2010year overall survival after the consolidation was 95% (95% CI, 74%\u201399%). In conclusion, in a subset of patients with previously treated FL,\n                    <jats:sup>90<\/jats:sup>\n                    Y\u2010IT consolidation after BR re\u2010induction conferred a durable remission, indicating that consolidation therapy using\n                    <jats:sup>90<\/jats:sup>\n                    Y\u2010IT may be a novel therapeutic option for patients with relapsed FL (UMIN000008793).\n                  <\/jats:p>","DOI":"10.1002\/hon.2809","type":"journal-article","created":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T01:30:05Z","timestamp":1601083805000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Consolidation with\n                    <sup>90<\/sup>\n                    Yttrium\u2010ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-3804","authenticated-orcid":false,"given":"Katsuhiro","family":"Miura","sequence":"first","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine Nihon University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tsujimura","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Chiba Cancer Center  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunology Kanazawa Medical University  Ishikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3471-0890","authenticated-orcid":false,"given":"Masaki","family":"Iino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Yamanashi Prefectural Central Hospital  Kofu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism Niigata University Faculty of Medicine  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology Okayama City Hospital  Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Kinan Hospital  Tanabe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology Toyama Prefectural Central Hospital  Toyama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Nara Prefecture General Medical Center  Nara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology National Hospital Organization Shikoku Cancer Center  Matsuyama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kitazume","sequence":"additional","affiliation":[{"name":"Department of Hematology Showa General Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Masunari","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Chugoku Central Hospital  Fukuyama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology National Hospital Organization Kyushu Cancer Center  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Kakinoki","sequence":"additional","affiliation":[{"name":"Department of Hematology Asahikawa City Hospital  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Oncology\/Hematology Innovative Cancer Center Shimane University Hospital  Izumo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Pathology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology and Biological Response Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology, Department of Medicine Nihon University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Member, Society of Lymphoma Treatment in Japan  Kashihara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kanno","sequence":"additional","affiliation":[{"name":"Oncology Center Nara Medical University Hospital  Kashihara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.03.005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-S2-17"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr418"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr145"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.684"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.790544"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1509322"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3755"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2513"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03750-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500376076"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1016929"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2809","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T09:58:51Z","timestamp":1693648731000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/hon.2809"],"URL":"https:\/\/doi.org\/10.1002\/hon.2809","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2809\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2809\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2809\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2809\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2809\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2809\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2809\/v3\/response1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"2020-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}